Pay in 4 interest-free payments of $5.38 Learn more
Ships within 48 hours · Estimated delivery Aug 12 - Aug 17
doi:10.1210/jc.20161257CrossRefGoogle ScholarPubMed Cherix, A., Larrieu, T., Grosse, J., Rodrigues, J., McEwen, B., Nasca, C., Sandi, C
An observational study published in the BMJ in 2016 found no increased risk of breast cancer among GLP-1 analog users when compared to DPP-4 inhibitor users (HR 1.40 (95%CI [0.91 to 2.16])
Intriguingly, GLP1/GIP had limited efficacy in our PCOS model with more severe metabolic complications, i.e., PWA mice fed HFD, suggesting that in the presence of persistently elevated androgen levels, its beneficial effects might be dampened
What's in it
US$ 21.82
US$ 25.02
US$ 27.88
